Harnessing Potential: Post-Operative Cataract Surgery Inflammation Treatment Market Forecast By 2023 to 2033

According to Future Market Insights, the global post-operative cataract surgery inflammation treatment market growth is projected to rise at a steady growth valued at US$ 4.56 billion 2023 with a 6.77% CAGR until 2033, being valued at US$ 8.78 billion. The rising number of cortical necrosis therapeutics are being delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries creates opportunities for market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

A lack of qualified personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global cataracts market over a forecast period. The huge expenditure associated with the treatment of cataracts surely hampers market growth. Increased approvals from FDA and more clinical research associated with cataracts are boosting the market growth. For instance, EyePoint Pharmaceuticals received FDA approval for Dexycu intraocular suspension in February 2018. This suspension is given as a single dose at the end of cataract surgery for the management of postoperative inflammation. The approval will help people across the world who are severe experiencing complications after cataract surgery. This boosts market growth.

Request A Sample Copy of This Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-16994

The prevalence of ocular pain keeps showing a surge in growth as chemical industries and pollution around the world are growing. Chemical burns and flash burns cause significant and severe ocular pain due to irritations over the eye surface. Style and blepharitis lead to severe ocular pain as they cause eye and oil glands to be more sensitive around the area.

Key Takeaways from the Market Study:

The market value in 2022 was US$ 4.045 Billion.
The global post-operative cataract surgery inflammation treatment grew at a CAGR of 6.45% from 2018 to 2022.
Increased approvals from FDA and more clinical research associated with cataracts are boosting the market growth.
UK-based subsidiary of Japanese ophthalmology firm Santen Pharmaceutical has announced the launch of Ducressa.
Allay Therapeutics, reported the first-ever clinical data showing non-opioid pain relief lasting two weeks after a single administration.
North America is said to dominate the market share followed by Asia-Pacific.

Competitive Landscape:

Some of the prominent players in the post-operative cataract surgery inflammation drug treatment market are-

Mallinckrodt Pharmaceuticals
Salix Pharmaceuticals
GlaxoSmithKline plc.
Pfizer Inc.
ASKA Pharmaceutical Co., Ltd.
Bausch Health
Johnson & Johnson Services, Inc.
Janssen Global Services
Takeda Pharmaceutical Company Limited
Merck & Co., Inc.

Some of the important developments of the key players in the market are:

In October 2022, Regeneron Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for EYLEA (aflibercept) Injection to treat Retinopathy of Prematurity (ROP) in preterm infants. This development helps the organization in developing its brand image in the ophthalmology market, among others.
In May 2022, Reichert, Inc. has launched its redesigned refractometers & analytical instruments website with a vastly improved user experience.

Key Segments Profiled in the Post-Operative Cataract Surgery Inflammation Drug Treatment Market:

By Drug Class: